Ponesimod

Ponvory (ponesimod) is a small molecule pharmaceutical. Ponesimod was first approved as Ponvory on 2021-03-18. It is used to treat relapsing-remitting multiple sclerosis in the USA. It has been approved in Europe to treat relapsing-remitting multiple sclerosis. The pharmaceutical is active against sphingosine 1-phosphate receptor 1 and sphingosine 1-phosphate receptor 5. In addition, it is known to target sphingosine 1-phosphate receptor 4 and sphingosine 1-phosphate receptor 3. Ponvory's patents are valid until 2035-12-10 (FDA).